Clinical Trial

Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is conducted to evaluate the efficacy and safety of lenvatinib plus SIRT (LEN+SIRT) compared with lenvatinib (LEN) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-25.
Status change: Not Yet Recruiting → Recruiting 2025-04-28
Trial Details
NCT Number NCT06904196
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Conditions Hepatocellular Carcinoma Non-resectable
Enrollment 78 participants
Start Date 2025-04-01
Primary Completion 2028-03-31 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-29